Blood Cancer Patient Outlives Prognosis by Years After Groundbreaking Drug Trial The latest results from a UK trial have sent shockwaves through the medical community, offering new hope for those battling high risk blood cancers like multiple myeloma.
For patients, this means a chance to live life on their own terms, free from the shackles of conventional treatment.
In 2018, Ken Theobold was given a stark prognosis: two years to live after being diagnosed with aggressive myeloma.